Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.44 |
| ▸ | FAAH | O00519 | 9/20 | 0.42 |
| ▸ | CES1 | P23141 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10451650 | 0.88 | CES2 (0.50) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL7100189 | 0.86 | MGAM (0.38) | CES2FAAHMGAMGAASI | |
| SCHEMBL23462201 | 0.85 | CES2 (0.61) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL23462144 | 0.85 | CES2 (0.61) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL5164255 | 0.85 | CES2 (0.61) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL5164217 | 0.84 | TSHR (0.50) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL77331 | 0.83 | GAA (0.61) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL5162657 | 0.82 | TSHR (0.48) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL7406648 | 0.81 | GAA (0.58) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL10139383 | 0.81 | TSHR (0.35) | CES2FAAHMEN1KMT2AMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658701-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORA-TIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2020-06-03 | — | — | EP | claimed |
| CN-110832110-A | Method for producing a metal nanoparticle layer and use thereof in decorative or security elements | 巴斯夫欧洲公司 | 2020-02-21 | — | — | CN | claimed |
| WO-2019020682-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORA-TIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2019-01-31 | — | — | WO | claimed |
| CN-107876092-A | The high stability titanium catalyst of ester exchange carbonate synthesis benzene methyl and diphenyl carbonate | 华东理工大学 | 2018-04-06 | — | — | CN | claimed |
| CN-107417719-A | A kind of titanium chelate catalyst for being used for carbonate synthesis benzene methyl and diphenyl carbonate | 华东理工大学 | 2017-12-01 | — | — | CN | claimed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-11643561-B2 | Process for the preparation of metallic nano-particle layers and their use for decorative or security elements | BASF SE | 2023-05-09 | — | — | US | disclosed |
| US-11643561-B2 | Process for the preparation of metallic nano-particle layers and their use for decorative or security elements | BASF SE | 2023-05-09 | — | — | US | disclosed |
| CN-107417719-B | Application of titanium chelate as reaction catalyst for synthesizing benzyl carbonate or diphenyl carbonate by ester exchange | 华东理工大学 | 2022-11-25 | — | — | CN | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200230646-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORATIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2020-07-23 | — | — | US | disclosed |
| WO-2020148780-A1 | PROCESS FOR PREPARATION OF 4,4,4- TRIFLUOROBUT-2-EN-1-OL AND INTERMEDIATE THEREOF | SRF LIMITED (IN) | 2020-07-23 | — | — | WO | disclosed |
| EP-3658701-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORA-TIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2020-06-03 | — | — | EP | disclosed |
| CN-110832110-A | Method for producing a metal nanoparticle layer and use thereof in decorative or security elements | 巴斯夫欧洲公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2019020682-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORA-TIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019020682-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORA-TIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2019-01-31 | — | — | WO | disclosed |
| CN-104030884-A | Preparation method of 2,3,3,3-tetrafluoropropylene | LINHAI LIMIN CHEMICALS CO LTD | 2014-09-10 | — | — | CN | disclosed |
| US-6893861-B1 | Method for producing trifluoro-3(r)-hydroxybutyric acid derivatives | LONZA AG (CH) | 2005-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | SCD5, SCD, FADS2 | CES2 543/4885FAAH 152/4885CES1 25/4885 |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | CES2 564/4885FAAH 158/4885CES1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.